Relmada Therapeutics (RLMD) Other Accumulated Expenses (2019 - 2026)
Relmada Therapeutics' (RLMD) quarterly Other Accumulated Expenses came in at $76100.0 in Q1 2026, up 12.57% year-on-year from $67600.0 in Q1 2025, and down 43.38% on a QoQ basis from $134400.0 in Q4 2025.
Relmada Therapeutics (RLMD) Other Accumulated Expenses (2019 - 2026) Analysis & Trends
Relmada Therapeutics (RLMD) has 6 years of Other Accumulated Expenses data on file, last reported at $76100.0 in Q1 2026.
- On a quarterly basis, Other Accumulated Expenses rose 12.57% year-over-year to $76100.0 in Q1 2026; TTM through Mar 2026 was $76100.0, a 12.57% increase from a year earlier, with the FY2025 full-year figure at $134400.0, up 3.86% from the prior year.
- Other Accumulated Expenses for Q1 2026 stood at $76100.0, down from $134400.0 in the prior quarter.
- Over the last five years, Other Accumulated Expenses for RLMD reached as high as $134400.0 in Q4 2025 and fell as low as $67600.0 in Q1 2025.
- Historically, Other Accumulated Expenses has averaged $95450.0 across 4 years, with a median of $80600.0 in 2024.
- Across the five-year window, Other Accumulated Expenses climbed 0.75% in 2025 and gained 12.57% in 2026, its largest moves.
- Year by year, Other Accumulated Expenses stood at $115500.0 in 2023, then climbed by 12.03% to $129400.0 in 2024, then rose by 3.86% to $134400.0 in 2025, then tumbled by 43.38% to $76100.0 in 2026.
- Per Business Quant data, the three most recent Other Accumulated Expenses figures were $76100.0 in Q1 2026, $134400.0 in Q4 2025, and $80900.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Relmada Therapeutics | 205.29 Mn | 205.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 76,100.00 |
| Dec 31, 2025 | 134,400.00 |
| Sep 30, 2025 | 80,900.00 |
| Jun 30, 2025 | 79,400.00 |
| Mar 31, 2025 | 67,600.00 |
| Dec 31, 2024 | 129,400.00 |
| Sep 30, 2024 | 80,300.00 |
| Dec 31, 2023 | 115,500.00 |
| Dec 31, 2020 | 126,200.00 |
| Jun 30, 2020 | 65,900.00 |
| Dec 31, 2019 | 92,900.00 |
| Sep 30, 2019 | 65,200.00 |
| Jun 30, 2019 | 59,400.00 |